A Prospective, Interventional, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of ImmunoSEB as Immunomodulator in Acute Allergic Rhinitis

Published: 21 October 2021| Version 1 | DOI: 10.17632/9c582b7rv3.1


In the current clinical trial, ImmunoSEB, a proprietary blend of systemic hydrolase enzymes (e.g., lysozyme, amyloglucosidase, catalase, peptizyme, serrapeptase, amylase, lactoferrin and papain) is used to evaluate their ability to induce immune system by modulating a series of inflammatory markers and immune cells in allergic rhinitis. ImmunoSEB was previously reported as biological response modifiers that has antibacterial, antimicrobial and immunomodulatory properties (Chitnis and Rathi, 2020). The present study highlights the efficacy and safety of ImmunoSEB to demonstrate immunomodulatory effect in acute allergic rhinitis.



Advanced Enzyme Technologies Ltd


Clinical Trial, Enzyme, Immunotherapy, Allergic Rhinitis, Clinical Trial Results